Knowledge and attitude of hereditary breast cancer among Japanese university female students. 2020

Hiroko Terui-Kohbata, and Makiko Egawa, and Kei Yura, and Masayuki Yoshida
Life Science and Bioethics Research Center, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo, Tokyo, 113-8510, Japan.

BRCA1/2 genetic testing to use PARP inhibitor for breast cancer has a possibility of the "secondary finding" among the younger nonaffected family members of the patient, which turns them into at-risk for hereditary breast cancer. Proper understanding of the background of the hereditary cancer is now required for appropriate acceptance of the risk. Therefore, we investigated the level of knowledge and attitudes of younger women on hereditary breast cancer in Japan. Study subject was Japanese university women between 20 and 30 years of age, without medical history of breast cancer. We conducted the anonymous self-answering questionnaire to them. We received responses from 353 women. The levels of knowledge, awareness, and interest were relatively high. Women with a family history of breast cancer were less likely to undergo testing than women without (92.8% vs. 74.5%, p < 0.001). The rates of positive response toward risk-reducing mastectomy (RRM) and risk-reducing salpingo-oophorectomy (RRSO) was significantly high for medical majors compared with that for other majors (RRM: medical 71.6% vs. science 54.5% vs. humanities 53.8%, p = 0.008, RRSO: 35.4% vs. 36.3% vs. 48.4%, p = 0.027). Approximately half of respondents answered that they would hesitate to get married (45.3%) or to have children (55.4%), if they were a BRCA1/2 mutation carrier. The results may help to establish the methods for supporting the decision-making for reproduction of younger women who are unexpectedly labeled as being at-risk for HBOC.

UI MeSH Term Description Entries
D007722 Health Knowledge, Attitudes, Practice Knowledge, attitudes, and associated behaviors which pertain to health-related topics such as PATHOLOGIC PROCESSES or diseases, their prevention, and treatment. This term refers to non-health workers and health workers (HEALTH PERSONNEL). Knowledge, Attitudes, Practice
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D005260 Female Females
D005820 Genetic Testing Detection of a MUTATION; GENOTYPE; KARYOTYPE; or specific ALLELES associated with genetic traits, heritable diseases, or predisposition to a disease, or that may lead to the disease in descendants. It includes prenatal genetic testing. Genetic Predisposition Testing,Genetic Screening,Predictive Genetic Testing,Predictive Testing, Genetic,Testing, Genetic Predisposition,Genetic Predictive Testing,Genetic Screenings,Genetic Testing, Predictive,Predisposition Testing, Genetic,Screening, Genetic,Screenings, Genetic,Testing, Genetic,Testing, Genetic Predictive,Testing, Predictive Genetic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000067856 Poly(ADP-ribose) Polymerase Inhibitors Chemicals and drugs that inhibit the action of POLY(ADP-RIBOSE)POLYMERASES. Inhibitors of Poly(ADP-ribose) Polymerase,PARP Inhibitor,Poly(ADP-Ribose) Polymerase Inhibitor,Poly(ADP-ribosylation) Inhibitor,Inhibitors of Poly(ADP-ribose) Polymerases,PARP Inhibitors,Poly(ADP-ribosylation) Inhibitors,Inhibitor, PARP,Inhibitors, PARP
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013334 Students Individuals enrolled in a school or formal educational program. School Enrollment,Enrollment, School,Enrollments, School,School Enrollments,Student
D014495 Universities Educational institutions providing facilities for teaching and research and authorized to grant academic degrees. University

Related Publications

Hiroko Terui-Kohbata, and Makiko Egawa, and Kei Yura, and Masayuki Yoshida
January 2019, Saudi journal of medicine & medical sciences,
Hiroko Terui-Kohbata, and Makiko Egawa, and Kei Yura, and Masayuki Yoshida
November 2010, Ethiopian journal of health sciences,
Hiroko Terui-Kohbata, and Makiko Egawa, and Kei Yura, and Masayuki Yoshida
January 2021, TheScientificWorldJournal,
Hiroko Terui-Kohbata, and Makiko Egawa, and Kei Yura, and Masayuki Yoshida
March 2018, Cureus,
Hiroko Terui-Kohbata, and Makiko Egawa, and Kei Yura, and Masayuki Yoshida
July 2015, Global journal of health science,
Hiroko Terui-Kohbata, and Makiko Egawa, and Kei Yura, and Masayuki Yoshida
January 2023, BMC women's health,
Hiroko Terui-Kohbata, and Makiko Egawa, and Kei Yura, and Masayuki Yoshida
February 2015, BMC research notes,
Hiroko Terui-Kohbata, and Makiko Egawa, and Kei Yura, and Masayuki Yoshida
January 2023, International journal of women's health,
Hiroko Terui-Kohbata, and Makiko Egawa, and Kei Yura, and Masayuki Yoshida
May 2018, Health care for women international,
Hiroko Terui-Kohbata, and Makiko Egawa, and Kei Yura, and Masayuki Yoshida
September 2012, Nursing & health sciences,
Copied contents to your clipboard!